# Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

> **NCT06937905** · PHASE3 · RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 129 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Standard of Care Chemotherapy
- **DRUG:** Tarlatamab

## Key facts

- **NCT ID:** NCT06937905
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2029-02-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06937905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06937905, "Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06937905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*